Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Sponsor
Novartis Pharmaceuticals
Study ID
NCT06858332
Status
Recruiting
Apply to this trial

Conditions

  • Atherosclerotic Cardiovascular Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Atorvastatin — DRUG
    3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
  • Simvastatin — DRUG
    3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
  • Rozuvastatin — DRUG
    3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)
  • Ezetimibe — DRUG
    Ezetimibe
  • Niacin — DRUG
    Niacin
  • Ciprofibrate — DRUG
    Fibrates
  • Fenofibrate — DRUG
    Fibrates
  • Bezafibrate — DRUG
    Fibrates
  • Evolocumab — DRUG
    PCSK9 inhibitor
  • Alirocumab — DRUG
    PCSK9 inhibitor
  • Inclisiran — DRUG
    Small interfering RNA

Study Details

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

Key Dates

Start date
Apr 15, 2025
Status verified
Jul 2025
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
2,382 participants (estimated)

Arms

  • Arm: ASCVD patients
    Patients aged 18 and above with a history of ASCVD including peripheral arterial revascularization
  • Arm: Relatives of the ASCVD patients
    A first-degree relative of the ASCVD patient (patient's parents and children) with Lp(a) ≥125 nmol/L.

Primary Outcome Measure

Percentage of patients (%) with Lp(a) ≥125 nmol/L [ Time Frame: Baseline ]

Central Contacts

Related Studies